PCM
GBT

Peregrine Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Peregrine Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-207,316
Closed -$11.4M – 391
2020
Q3 		$11.4M Sell
207,316
-2,338
-1% -$149K 0.3% 121
2020
Q2 		$13.2M Buy
209,654
+8,556
+4% +$587K 0.38% 108
2020
Q1 		$10.3M Buy
+201,098
New +$13.5M 0.37% 112

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Peregrine Capital Management's GBT Position: Q4 2020 in Review

Peregrine Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 207,316 shares — an estimated $11.4M sold.

Peregrine Capital Management first reported a position in GBT in Q1 2020 and held it in 3 quarters. The position peaked at $13.2M in Q2 2020. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

  • Peregrine Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Peregrine Capital Management sold 207,316 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $11.4M.
  • Peregrine Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2020 and held it in 3 quarters.
  • Peregrine Capital Management's Global Blood Therapeutics, Inc. position peaked at $13.2M in Q2 2020.
  • 228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Peregrine Capital Management's 13F filing for Q4 2020, filed 19 Jan 2021.